Home healthcare visits may reduce the need for on-site procedures, but they don’t eliminate the site’s workload. Learn how to budget PI oversight, coordinator tasks, and vendor-performed procedures without underpaying sites or creating duplicate fees.
If you build global budgets, Japan is the country that doesn’t fit the template. No grid, no line-by-line check against your FMV tool. Just a cost per patient, a few institution fees, and a note that medical expenses will be billed separately. Here’s what a Japanese budget looks like, why it’s built that way, and where the switch to FMV really stands.
A practical introduction to Veeva Vault for clinical trial budget analysts, covering document lifecycles, workflows, version control, audit trails, and what to do when things go wrong. Based on experience working on Takeda studies.
A practical guide to clinical trial budgeting in Belgium, covering the regulatory timeline, site setup requirements, patient reimbursement, contracts, Power of Attorney, GDPR, withholding, and payment considerations for IGAs and budget developers.
A Start-up total that looks reasonable isn't the same as one that's been tested against the study. Here's how to benchmark Start-up requests from first principles, spot the line items that deserve a second look, and write payment terms that protect the sponsor if a site never activates.
Site fees are the least standardized, most inconsistently named part of any CTA and Start-up is where it gets worst. Here's how to break black-box start-up fees into specific, verifiable activities you can actually evaluate.
If you've built an observational study budget, you know it's one of the simpler builds you'll encounter - lean SOEs, no IP administration, no PK draws. But why do these studies exist at all, and why does a drug that just finished a multi-thousand-patient Phase III program need more data collected on it? This article breaks down the logic behind observational research, the different study types you'll encounter, and what it actually means for the work on your desk.
Take one protocol, hand it to three experienced budget analysts, and ask each of them to build a study budget independently. You'll get three defensible grids - each internally consistent, each arguably correct, each slightly different. None of them are wrong. That's exactly the problem AI is about to make impossible to ignore.
AI is not eliminating clinical trial budget analyst roles - it is changing them. As protocol-to-budget automation improves, the profession is increasingly dividing into two distinct paths: reviewers who validate AI-generated budgets and strategists who focus on FMV, negotiations, country-specific costs, and stakeholder management.
This article breaks down the real skills behind career progression at every level - from becoming reliable as a junior analyst to driving strategy and influence at the lead and principal level.
